← Eichor
Study identifier: NCT05564949 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases

Condition: Brain · Cancer  ·  Sponsor: Attikon Hospital

PhaseNA
Planned participants15
Who can joinAll sexes, 18 Years to 80 Years
Healthy volunteersNo

About this study

The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.

This description comes directly from the study's public registry record.

Talk to the study team

Arezina N. Kasti, RD  ·  +306942917860  ·  kastiare@yahoo.gr

Evangelos K. Papadopoulos, MD  ·  6936251274  ·  neuroevan@yahoo.gr

Always discuss trial participation with your own doctor first.

Locations (2)

Arezina KastiChaïdári, Athens, GreeceRecruiting
Attikon University General HospitalAthens, GreeceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05564949